Key Takeaways
💰 LLY offers a forward dividend yield of 0.57% with a recent quarterly increase to $1.73 per share, reflecting continued commitment to dividend growth with a conservative payout ratio of just 26%.
💵 Operating cash flow reached $16.8 billion over the trailing twelve months, reflecting the dramatic revenue ramp driven by GLP-1 drug adoption globally.
📊 The consensus analyst price target is $1,212.82 across 28 analysts, suggesting meaningful upside from the current price of $1,042.15.
📈 Full-year revenue came in at $65.2 billion, with net income of $20.6 billion and a profit margin of nearly 32%, underscoring the sheer earnings power this business has developed.
Updated 2/25/26
Eli Lilly (LLY) has cemented its status as one of the most consequential pharmaceutical companies in the world, riding a historic wave of demand for its GLP-1 therapies in diabetes and obesity care. Revenue has scaled dramatically, profit margins have expanded, and the company’s earnings power continues to impress even at its current size. Management has kept pace with demand through aggressive manufacturing investment and disciplined capital planning, all while maintaining a consistent and growing dividend.
While the yield remains modest by income standards, the payout is backed by one of the strongest earnings profiles in the healthcare sector. A robust pipeline, market-leading therapies, and a long-term growth orientation have positioned Lilly for sustained performance across multiple therapeutic categories.
Recent Events
Eli Lilly has been navigating a dynamic environment heading into early 2026, with investor attention focused on the continued global rollout of Mounjaro and Zepbound, its flagship GLP-1 therapies. Both drugs have continued to capture market share in the diabetes and obesity segments, and international expansion efforts have added a meaningful new growth dimension as access improves in European and Asian markets. Manufacturing capacity has been a persistent theme, with the company pressing forward on multiple new facilities to meet demand that continues to outpace supply in certain geographies.
On the pipeline front, Lilly has been advancing its oral GLP-1 candidate orforglipron through late-stage trials, with investor anticipation building around what a successful approval could mean for broadening the addressable market beyond injectable therapies. Progress in Alzheimer’s and oncology has also kept the pipeline narrative intact, providing additional catalysts beyond the core obesity and diabetes franchise.
The company also raised its quarterly dividend to $1.73 per share, payable in February 2026, marking a meaningful step up from the $1.50 per share rate that held throughout 2025. That increase of roughly 15% signals confidence from the board in the durability of the company’s earnings and cash flow. For dividend-focused investors, it reinforces that Lilly views the payout as a key component of its capital return strategy even as it invests heavily in growth.
Key Dividend Metrics
💰 Forward Dividend Yield: 0.57%
📈 Annual Dividend Rate: $6.23 (annualized from most recent quarterly payment of $1.73)
📆 Most Recent Dividend Payment: February 13, 2026
📊 Payout Ratio: 26.14%
📉 5-Year Average Yield: 1.13%
📈 Dividend Growth Trend: Upward, with an accelerating pace of recent increases
📌 Next Likely Declaration: Summer 2026
Dividend Overview
Lilly has never been a yield story, and at 0.57% that remains firmly true. But the dividend picture here is more compelling than the yield figure alone suggests. The quarterly payment was just raised to $1.73 per share in February 2026, up from $1.50 per share throughout 2025 and $1.30 per share throughout 2024. That trajectory represents a meaningful and accelerating pace of dividend growth rooted in genuine earnings expansion, not financial engineering.
The payout ratio tells the real story. At just 26% of earnings, Lilly is paying out a very small fraction of what it earns, which means the dividend is extraordinarily well protected and has substantial room to grow. With EPS running at $22.93 and an annual dividend of $6.23, the company is retaining the vast majority of its profits for reinvestment while still delivering consistent raises to shareholders. That is the hallmark of a dividend with genuine upside optionality.
This is a company generating $16.8 billion in operating cash flow and earning a return on equity above 100%. Income investors who look past the yield and focus on dividend safety, growth trajectory, and underlying earnings quality will find Lilly occupying rare territory. It is not built for current income, but for compounding income over time alongside meaningful capital appreciation potential.
Dividend Growth and Safety
The dividend history over the past three years tells a clear story of deliberate acceleration. Lilly held its quarterly payment at $1.13 per share through most of 2023, then raised it to $1.30 in early 2024, to $1.50 in early 2025, and most recently to $1.73 in February 2026. Each of those increases came alongside strengthening financial results, meaning the raises have been earned rather than stretched.
Safety is not a concern at these payout levels. Operating cash flow of $16.8 billion dwarfs the dividend obligation, and net income of $20.6 billion provides enormous coverage. Even accounting for the heavy capital expenditure program the company is running to expand manufacturing infrastructure, the dividend is in no danger. Free cash flow came in at $1.95 billion for the period, which is tighter than the operating cash flow figure implies, but that gap reflects the scale of reinvestment Lilly is making in its own capacity, not any weakness in the underlying business.
The return on equity above 101% and a profit margin approaching 32% speak to the quality of earnings supporting this payout. Debt is elevated in absolute terms, as it has been in prior periods, but Lilly’s ability to generate cash at this scale makes the leverage manageable within the context of its earnings profile. The board’s consistent willingness to raise the dividend even as it funds aggressive growth investment suggests no tension between the two priorities. For investors with a long time horizon, the combination of a low payout ratio, rising earnings, and an accelerating raise cadence makes LLY one of the more attractive dividend growth stories in large-cap healthcare.
Chart Analysis
Eli Lilly has delivered a remarkable run over the past year, with the stock climbing from a 52-week low of $622.32 to a high of $1,108.09 before settling at its current price of $1,042.15. That translates to a gain of more than 67% from the annual trough, a move driven largely by the explosive commercial momentum behind Mounjaro and Zepbound. The stock’s ability to hold above the four-figure level even after pulling back roughly 6% from its peak suggests that institutional demand remains constructive and that the broader uptrend is intact rather than exhausted.
The moving average picture reinforces that longer-term bullish view. LLY is trading well above its 200-day moving average of $867.38, sitting approximately 20% above that long-term trend line, which reflects the sustained repricing the market has applied to the company’s growth prospects. The 50-day moving average currently sits at $1,051.50, just a fraction above the current price, meaning LLY has slipped into a near-term consolidation zone beneath that shorter-term trend measure. Critically, the 50-day remains comfortably above the 200-day, confirming a golden cross formation that technical analysts treat as a structurally bullish signal for intermediate-term trend direction.
At an RSI reading of 55.08, LLY sits in a neutral-to-mildly-positive momentum zone, well clear of the overbought territory above 70 that characterized several points during its rapid ascent. This is a constructive setup for income investors who were priced out during the more parabolic phases of the rally. The cooling in momentum does not signal deterioration in the underlying trend; it reflects a healthy digestion of prior gains, and a stock consolidating near its highs with a mid-range RSI is often better positioned for the next leg than one that has been driven into overbought conditions.
For dividend investors, the chart tells a story of a stock in a durable uptrend that is currently pausing near a logical area of support around its 50-day moving average. The distance from the 52-week low of over 67% is a reminder that entry point matters considerably for total return, and investors adding a position today are doing so with the stock well off its lows but also not at a stretched valuation from a technical momentum standpoint. The combination of a golden cross, a neutral RSI, and price holding well above the 200-day moving average suggests the path of least resistance remains upward, though a clean reclaim of the $1,051 level on strong volume would be a more decisive confirmation that the consolidation phase has run its course.
Cash Flow Statement
Eli Lilly’s cash flow profile has undergone a dramatic transformation over the past three years, and the 2025 figures make a compelling case for dividend sustainability. Operating cash flow surged to $16,813.0 million in 2025, more than doubling the $8,818.0 million generated in 2024 and dwarfing the trough of $4,240.0 million recorded in 2023. Free cash flow tells a similarly encouraging story, recovering to $5,964.0 million in 2025 after a deeply negative $3,152.0 million in 2023, when the company was pouring capital into manufacturing capacity for its GLP-1 franchise. With Lilly’s annualized dividend obligation running well below that free cash flow figure, the payout is covered comfortably on a cash basis, which is precisely the kind of structural support income investors want to see behind a growth-oriented dividend grower.
The multi-year trajectory here reflects a classic capital investment cycle playing out in real time. The 2023 free cash flow collapse was not a sign of operational distress but rather the consequence of aggressive capacity expansion, with capital expenditures consuming the bulk of operating cash in anticipation of demand that has since arrived at scale. The rebound to $8,818.0 million in operating cash flow for 2024, followed by the leap to $16,813.0 million in 2025, confirms that those investments are now generating returns. The TTM free cash flow of $1,951.0 million sits below the full-year 2025 figure, suggesting that capital spending remains elevated on a trailing basis as Lilly continues to build out its manufacturing footprint, but the operating cash generation underneath that spending is robust and accelerating. For shareholders, the key takeaway is that Lilly has reached an inflection point where its commercial infrastructure is beginning to convert extraordinary revenue growth into extraordinary cash, providing a durable and expanding foundation for future dividend increases.
Analyst Ratings
Analyst sentiment on Eli Lilly remains broadly constructive heading into late February 2026. Across 28 analysts covering the stock, the consensus sits at buy, with a mean price target of $1,212.82 against a current price of $1,042.15. That implies roughly 16% upside to the consensus target from current levels, which is a meaningful gap for a company of this size and quality.
The range of targets is wide, reflecting genuine disagreement about where Lilly’s earnings trajectory ultimately leads. The low end of the range sits at $870.00, reflecting analysts who are more cautious about valuation or competition in the GLP-1 market, while the high end reaches $1,500.00 from those who see continued volume ramp and pipeline optionality as justifying a premium multiple. The spread between those extremes illustrates how much of Lilly’s valuation hinges on assumptions about long-term drug demand and pipeline success.
The broader analyst community continues to favor Lilly’s leadership position in obesity and diabetes, and enthusiasm around orforglipron as an oral GLP-1 candidate has added a new dimension to the bull case. While some analysts have flagged valuation as a near-term concern given the stock’s run from its 52-week low of $623.78, the prevailing view is that the company’s earnings power and pipeline depth justify a premium to traditional pharma multiples. At the current price, the stock sits well below its 52-week high of $1,133.95, which has brought some of the more aggressive valuation concerns back toward neutral.
Earning Report Summary
Big Revenue Gains from Key Drugs
Eli Lilly’s full-year financial results for the period ending in early 2026 reflect a company that has fully transitioned from a promising growth story into a large-scale earnings machine. Revenue came in at $65.2 billion, a figure that would have seemed implausible just a few years ago and one that reflects the extraordinary commercial success of its GLP-1 portfolio. Mounjaro and Zepbound continued to lead the way, driving volume gains both domestically and internationally as access and manufacturing capacity improved. The obesity treatment market has proven far larger than early skeptics anticipated, and Lilly has captured a leading share of that demand.
Strong Earnings with Improving Margins
Net income reached $20.6 billion, translating to earnings per share of $22.93 and a profit margin of nearly 32%. Return on equity surpassed 100%, reflecting the exceptional profitability the company has achieved at this revenue scale. Operating cash flow of $16.8 billion confirms that earnings are translating into real cash generation. The tighter free cash flow figure of $1.95 billion is a function of elevated capital expenditures tied to manufacturing expansion rather than any deterioration in the business model. The underlying earnings quality is high, with operating and net margins both at levels that rank among the best in large-cap pharmaceuticals.
Leadership’s Outlook and What’s Ahead
CEO David Ricks has consistently framed the current investment cycle as a necessary bridge to capturing a generational market opportunity in metabolic disease and beyond. Manufacturing expansion remains a top priority, with multiple new facilities in development to ensure Lilly can meet demand as it continues to scale internationally. The pipeline is also advancing, with orforglipron representing a potentially significant commercial opportunity if late-stage trial results support approval. Alzheimer’s and oncology programs provide additional optionality beyond the core GLP-1 franchise.
The company enters 2026 with one of the strongest earnings profiles in its history, a conservative dividend payout, and a pipeline that gives investors reasons to believe the growth story is not yet fully told. The challenge ahead is maintaining execution at scale while managing the competitive dynamics of a GLP-1 market that is attracting increasing attention from rival pharmaceutical companies. For now, Lilly’s commercial and scientific advantages appear durable.
Management Team
Eli Lilly’s executive leadership remains one of its quiet strengths. At the helm, CEO David Ricks has guided the company through a pivotal transformation since stepping into the role in 2017. Under his leadership, Lilly has become a global leader in high-impact areas like diabetes, obesity, and neuroscience. Ricks has prioritized long-term investment over short-term earnings beats, a philosophy that has helped the company build durable advantages in its most lucrative categories and that continues to shape capital allocation decisions even as the business scales to new heights.
Chief Financial Officer Anat Ashkenazi continues to play a key role in balancing the demands of aggressive R&D spending and manufacturing investment with prudent cash management. Her financial strategy has helped maintain a strong balance sheet while the company deploys billions into scaling up production capacity and funding clinical programs. That discipline has been essential in supporting both the dividend and the company’s ambitious growth plans, and it is reflected in the conservative payout ratio that leaves substantial room for future dividend increases.
The broader leadership team brings a mix of operational depth and scientific expertise. Their focus on pipeline development, global commercial expansion, and infrastructure buildout has laid a strong foundation for sustained growth. It is a group that operates with clear strategic intent and a long-term view, staying grounded in execution even as investor attention shifts rapidly between blockbuster drug headlines and competitive threats. That steadiness at the top has been a meaningful source of stability for the business.
Valuation and Stock Performance
LLY is trading at $1,042.15 as of late February 2026, sitting below its 52-week high of $1,133.95 but well above the 52-week low of $623.78, which reflects the significant drawdown the stock experienced at various points over the past year. The current price implies a trailing P/E of 45.45, a price-to-book of 35.14, and a market capitalization approaching $983 billion. By conventional standards those multiples look demanding, but they need to be evaluated against a business generating over $20 billion in net income and growing revenue at a pace that few companies of this scale can match.
The stock’s beta of 0.39 is notably low for a company with this level of earnings momentum, reflecting the defensive quality that investors have historically attributed to Lilly’s business model even during periods of broader market volatility. That low beta has made LLY an attractive holding for investors seeking growth with reduced correlation to market swings, and it has helped cushion drawdowns during risk-off periods.
At the current price, the stock trades at a meaningful discount to the analyst consensus target of $1,212.82, which represents roughly 16% upside to the mean estimate. That gap, combined with the earnings trajectory and pipeline catalysts, suggests the market is pricing in some degree of execution risk or competitive concern rather than reflecting unambiguous optimism. Whether that discount represents an opportunity depends heavily on one’s conviction in the GLP-1 market’s long-term growth and Lilly’s ability to maintain its competitive position within it. For investors with a multi-year horizon, the combination of earnings growth, dividend growth, and a below-consensus price creates a reasonable entry point relative to recent highs.
Risks and Considerations
Competition in the GLP-1 market is intensifying and represents the most significant near-term risk to Lilly’s revenue trajectory. Several large pharmaceutical companies are advancing their own obesity and diabetes treatments, and if a rival drug demonstrates superior efficacy, a more convenient delivery mechanism, or a more favorable side effect profile, Lilly’s market share could erode faster than current projections assume. The company’s pricing power could also come under pressure as the category becomes more crowded.
Drug pricing policy remains an active political and regulatory risk. Lilly’s GLP-1 therapies have attracted significant attention from lawmakers and payers given their high costs and broad patient populations. Any legislative changes that cap prices, alter reimbursement structures, or impose rebate requirements could have a direct and material impact on revenue and margins. The policy environment around pharmaceutical pricing has been volatile in recent years and is unlikely to become more favorable in the near term.
The capital expenditure program tied to manufacturing expansion is substantial and creates execution risk. Building large-scale pharmaceutical manufacturing facilities on an accelerated timeline is operationally complex, and delays, cost overruns, or quality issues could strain free cash flow and slow the company’s ability to meet demand in new markets. Free cash flow is already compressed by the scale of these investments, and any unexpected increase in capital requirements could limit financial flexibility.
Finally, Lilly’s earnings are still heavily concentrated in a relatively narrow set of products. While the pipeline is deep and advancing, the commercial portfolio’s dependence on Mounjaro and Zepbound means that any setback affecting those franchises, whether from safety findings, competitive displacement, or a slower-than-expected international rollout, could result in a sharp reassessment of the stock’s premium valuation. Pipeline assets carry their own risks, as late-stage trial failures are a routine feature of pharmaceutical development regardless of how promising early data appears.
Final Thoughts
Eli Lilly enters early 2026 as one of the most financially powerful companies in the healthcare sector, with revenue of $65.2 billion, net income exceeding $20 billion, and a dividend that has been raised three consecutive years with the most recent increase of approximately 15% arriving in February 2026. The business has moved past the early growth phase of its GLP-1 story and into a period of large-scale commercial execution, which brings both the rewards of proven demand and the challenge of sustaining growth at an increasingly large base.
The dividend picture is genuinely attractive for long-term income growth investors. A payout ratio of just 26% means there is enormous capacity for continued raises even if earnings growth moderates, and the trajectory of recent increases suggests the board is committed to accelerating shareholder returns as cash flow expands. This is not a stock you buy for current income, but for compounding income over time alongside a business that is reshaping the global treatment landscape for metabolic disease.
The risks are real and should not be minimized. Competition will intensify, policy risk is persistent, and the stock’s current valuation leaves limited room for disappointment. But those risks are balanced against a management team with a demonstrated track record, a pipeline with multiple near-term catalysts, and a competitive position in a therapeutic area that is still in the early stages of global adoption. For investors with the patience and conviction to hold through volatility, Lilly remains one of the more compelling combinations of quality, growth, and dividend momentum available in large-cap healthcare.